Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

Inclusion Criteria: * BMI between ≥18 kg/m² and \<30 kg/m² at time of screening * Body weight between ≥45 kg and \<100 kg * Baseline vWF:Ag between ≥60% and \<170% (0.6-1.7 IU/mL) Exclusion Criteria: * History of and/or any sign or symptom indicating current abnormal hemostasis or blood dyscrasia, including but not limited to thrombocytopenia, thrombocytopathy, thromboasthenia, hemophilia, von Willebrand's disease, vascular purpura, bleeding gums and/or frequent nose bleeding, easy/spontaneous bruises, meno- or metrorrhagia, history of gastrointestinal bleeding or excessive bleeding after minor injury such as shaving. * Family history of congenital vascular malformation (e.g., Marfan's Syndrome) and/or bleeding disorder (e.g., hemophilia, von Willebrand's disease, Christmas disease) * Any surgical intervention (including tooth extraction) or trauma within the 4 weeks preceding screening for the study or any planned surgical intervention during the participation in the study * Treatment with vitamin K, direct oral anticoagulant (DOAC), warfarin, high dose heparin within 2 weeks before screening